Cidara Therapeutics Inc (CDTX)
20.68
+3.23
(+18.51%)
USD |
NASDAQ |
Nov 22, 16:00
21.31
+0.63
(+3.05%)
After-Hours: 20:00
Cidara Therapeutics Total Liabilities (Quarterly): 46.70M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 46.70M |
June 30, 2024 | 42.42M |
March 31, 2024 | 70.50M |
December 31, 2023 | 75.24M |
September 30, 2023 | 55.43M |
June 30, 2023 | 52.57M |
March 31, 2023 | 54.90M |
December 31, 2022 | 61.92M |
September 30, 2022 | 57.79M |
June 30, 2022 | 47.48M |
March 31, 2022 | 50.34M |
December 31, 2021 | 53.75M |
September 30, 2021 | 52.36M |
June 30, 2021 | 47.96M |
March 31, 2021 | 52.32M |
December 31, 2020 | 49.71M |
September 30, 2020 | 34.12M |
June 30, 2020 | 32.05M |
March 31, 2020 | 30.34M |
December 31, 2019 | 31.14M |
Date | Value |
---|---|
September 30, 2019 | 32.73M |
June 30, 2019 | 19.97M |
March 31, 2019 | 20.45M |
December 31, 2018 | 19.97M |
September 30, 2018 | 22.88M |
June 30, 2018 | 24.87M |
March 31, 2018 | 19.33M |
December 31, 2017 | 19.29M |
September 30, 2017 | 16.86M |
June 30, 2017 | 19.89M |
March 31, 2017 | 16.77M |
December 31, 2016 | 18.78M |
September 30, 2016 | 8.317M |
June 30, 2016 | 5.215M |
March 31, 2016 | 4.145M |
December 31, 2015 | 6.062M |
September 30, 2015 | 4.363M |
June 30, 2015 | 3.096M |
March 31, 2015 | 78.31M |
December 31, 2014 | 35.80M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
30.34M
Minimum
Mar 2020
75.24M
Maximum
Dec 2023
49.95M
Average
51.33M
Median
Total Liabilities (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 1.438B |
Arbutus Biopharma Corp | 33.55M |
GlycoMimetics Inc | 4.322M |
FibroGen Inc | 466.12M |
Cue Biopharma Inc | 19.44M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 162.33M |
Shareholders Equity (Quarterly) | 115.63M |